“COVID19 was a gift to shareholders.” Yes a
Post# of 148288
(Total Views: 394)
Posted On: 04/17/2020 11:05:08 AM
“COVID19 was a gift to shareholders.”
Yes and an indication that is going to cost CYDY greatly in the cash department, something the company struggles to raise without dilution. I’m unsure how long CYDY can maintain the current cash burn, even with warrants being conveyed, before having to raise more funds to move the COVID trials, cancer trials, and BLA along. Oh, and to pay for all the advertising via proactive, Wall Street reporter, and other online publications.
“When approved we will be at a complete different level. It Should generate billions in revenue in 2020 alone.”
You’ll have to explain to me how CYDY is going to make billions off COVID19 in 2020. I’m hopeful leronlimab gets approval to treat COVID19, but even if it does, not every person diagnosed with COVID19 will receive it. What’s more likely is that COVID19 patients that have comorbidities and that are at a high risk for hospitalization will receive the medication. What percentage of positive COVID19 patients is that? That’s a good question. And when approval comes, will the world be on the down slope of the curve and they’ll be a smaller pool of patients to treat? Also, what will CYDY charge for a treatment?
Yes and an indication that is going to cost CYDY greatly in the cash department, something the company struggles to raise without dilution. I’m unsure how long CYDY can maintain the current cash burn, even with warrants being conveyed, before having to raise more funds to move the COVID trials, cancer trials, and BLA along. Oh, and to pay for all the advertising via proactive, Wall Street reporter, and other online publications.
“When approved we will be at a complete different level. It Should generate billions in revenue in 2020 alone.”
You’ll have to explain to me how CYDY is going to make billions off COVID19 in 2020. I’m hopeful leronlimab gets approval to treat COVID19, but even if it does, not every person diagnosed with COVID19 will receive it. What’s more likely is that COVID19 patients that have comorbidities and that are at a high risk for hospitalization will receive the medication. What percentage of positive COVID19 patients is that? That’s a good question. And when approval comes, will the world be on the down slope of the curve and they’ll be a smaller pool of patients to treat? Also, what will CYDY charge for a treatment?
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼